Emcure Pharmaceuticals today said it has filed a draft red herring prospectus (DRHP) with the SEBI for launching an initial public offer to raise an estimated Rs 300 crore.
The IPO comprises a fresh issue of equity shares aggregating up to Rs 300 crore and an offer for sale of up to 2,513,057 equity shares by certain existing shareholders of the company, a statement issued here said.
The equity shares of face value Rs 10 each offered in the issue are proposed to be listed on BSE Ltd and the National Stock Exchange of India Ltd (NSE).
The book running lead managers to the issue are DSP Merrill Lynch Ltd, IDFC Capital Ltd and Morgan Stanley India Company Private Ltd.
Emcure is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally.
The company commercialises its products through a combination of its own marketing and distribution infrastructure. It has subsidiaries in Brazil, Dubai, Nigeria, Singapore and South Africa and branch offices in Morocco and Russia, which play an important role in its international operations, the release said.